The role of Fc receptors in HIV prevention and therapy

Immunol Rev. 2015 Nov;268(1):296-310. doi: 10.1111/imr.12339.


Over the past decade, a wealth of experimental evidence has accumulated supporting the importance of Fc receptor (FcR) ligation in antibody-mediated pathology and protection in many disease states. Here we present the diverse evidence base that has accumulated as to the importance of antibody effector functions in the setting of HIV prevention and therapy, including clinical correlates, genetic associations, viral evasion strategies, and a rapidly growing number of compelling animal model experiments. Collectively, this work identifies antibody interactions with FcR as important to both therapeutic and prophylactic strategies involving both passive and active immunity. These findings mirror those in other fields as investigators continue to work toward identifying the right antibodies and the right effectors to be present at the right sites at the right time.

Keywords: Fc receptor; HIV; IgA; IgG; antibody; effector function.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / immunology
  • Animals
  • Antibody-Dependent Cell Cytotoxicity / immunology
  • Disease Models, Animal
  • Genetic Variation
  • HIV Antibodies / immunology*
  • HIV Antibodies / metabolism*
  • HIV Infections / metabolism*
  • HIV Infections / prevention & control*
  • HIV Infections / therapy*
  • HIV Infections / virology
  • HIV-1 / immunology*
  • Host-Pathogen Interactions / genetics
  • Host-Pathogen Interactions / immunology
  • Humans
  • Immune Evasion
  • Immunization, Passive
  • Immunoglobulin A / immunology
  • Immunoglobulin A / metabolism
  • Protein Binding
  • Receptors, Fc / classification
  • Receptors, Fc / genetics
  • Receptors, Fc / metabolism*


  • AIDS Vaccines
  • HIV Antibodies
  • Immunoglobulin A
  • Receptors, Fc